IL-10 Modulator

VO-OHPic is a reversible, noncompetitive PTEN inhibitor with an human IC₅₀ value of 46 nM. VO-OHPic inhibits PTEN signaling, activates Akt-GSK3β and Nrf-2/HO-1 pathways, induces apoptosis resistance and elevates IL-10 levels. VO-OHPic inhibits autophagy, ferroptosis and oxidative stress. VO-OHPic can be used for the research of acute myocardial infarction, intervertebral disc degeneration, cardiomyopathy and cancer.

RO8323 is an orally active, selective CDK8/CDK19 inhibitor, with an IC₅₀ of 2 nM against CDK8 and 3 nM against CDK19. RO8323 promotes regulatory T cell differentiation, inhibits effector T cell generation, reverses the Teff/Treg ratio, upregulates IL-10 production in myeloid cells, and suppresses the production of TNF-α, IL-6 and IL-12. RO8323 enhances immune reconstitution and prolongs cardiac allograft survival in a dose-dependent manner. RO8323 can be used in the research of chronic graft-versus-host disease, cardiac allograft rejection, acute graft-versus-host disease and experimental autoimmune encephalomyelitis.

2-ARA-LysoPtdEtn (1-Lyso-2-arachidonoyl-sn-glycero-3-phosphoethanolamine) is an orally active polyunsaturated acyl lysophosphatidylethanolamine. 2-ARA-LysoPtdEtn diminishes formation of LTC₄, LTB₄, and 12-HETE. 2-ARA-LysoPtdEtn lowers levels of IL-1β, IL-6, TNF-α, and NO. 2-ARA-LysoPtdEtn augments IL-10 levels and upgrades formation of 15-HETE and LXA₄. 2-ARA-LysoPtdEtn can be used for the research of peritonitis.

Lemairamin (Wgx-50) is a hydroxylamine compound. Lemairamin can be isolated from the pericarps of the Zanthoxylum plants. Lemairamin activates α7nAChR, stimulates the expression of IL-10 and POMC. Lemairamin shows a decrease in Akt. Lemairamin attenuates DSS-induced intestinal inflammation. Lemairamin alleviates pain hypersensitivity.

PKR1 antagonist-2 is a non-peptide prokineticin receptor antagonist that preferentially binds to and blocks PK-R1 signaling while also blocking PK-R2. PKR1 antagonist-2 shifts the autoimmune response against myelin from a Th1/Th17 profile toward a Th2 profile, reducing myelin antigen-specific T cell proliferation and the production of proinflammatory cytokines (IFN-γ, TNF, IL-6, IL-17), and increasing the levels of anti-inflammatory cytokines IL-4/IL-10. PKR1 antagonist-2 significantly alleviates disease severity in relapsing-remitting and chronic experimental autoimmune encephalomyelitis (EAE). PKR1 antagonist-2 can be used in research related to multiple sclerosis .

PNA5 is a novel, blood-brain barrier permeable glycosylated angiotensin-(1-7) peptide and MasR agonist. PNA5 inhibits IL-7, increases IL-10. PNA5 inhibits ROS generation, decreases Iba-1 expression. PNA5 exhibits sustained cognitive protective effects. PNA5 rescues blunted cerebral functional hyperemia. PNA5 can be used in the research of inflammation-related brain diseases.

cyclo-Cannabigerol (cyclo-CBG) is the major metabolite of Cannabigerol generated by cytochrome P450. Cyclo-Cannabigerol has weak anti-inflammatory activity.

13 (S)-HOTrE is an oxylipin metabolite of α-Linolenic acid (HY-N0728). 13 (S)-HOTrE mediates the inactivation of the NLRP3 inflammasome through the PPAR-γ pathway to exert anti-inflammatory effects. 13 (S)-HOTrE inhibits NF-κB nuclear translocation, ROS production, autophagy and IL-1β levels, induces apoptosis, and increases IL-10 levels. 13 (S)-HOTrE alleviates LPS-induced inflammatory responses in macrophages, prolongs the survival time of septic mice, and regulates the immunometabolic phenotype in parenteral nutrition mouse models. 13 (S)-HOTrE can be used in the research of immune and inflammation-related diseases.

Pseudoginsenoside RT4 is an orally active anti-inflammatory agent. Pseudoginsenoside RT4 can be isolated from Panax pseudoginseng subsp. Himalaicus, Panax vietnamensis Ha et Grushv, and Panax quinquefolius L. Pseudoginsenoside RT4 reduces the levels of TNF-α, IL-6, and IL-1β, elevates the level of IL-10, improves the histopathological features of colon tissue, maintains the ultrastructure of colonic epithelium, protects the integrity of cell monolayers, increases the expression of tight junction proteins, raises the total content of short-chain fatty acids, corrects intestinal flora disorder, reduces the disease activity index score, restores colon length, and decreases the spleen index. Pseudoginsenoside RT4 exhibits hepatoprotective effects. Pseudoginsenoside RT4 can be used in studies related to ulcerative colitis.

Carboetomidate is a pyrrole derivative analogous to the sedative-hypnotic drug Etomidate, which induces general anesthesia while avoiding the inhibition of adrenal steroid synthesis. Carboetomidate enhances GABA_A receptor function via β2/β3 subunits, inhibits neuronal nicotinic acetylcholine receptors (nAChR) and 5-HT₃A receptors, and increases plasma IL-10 levels during endotoxemia. Carboetomidate is applicable to research related to sepsis and sleep disorders.

(E)-Methyl 4-coumarate (Standard) is the analytical standard of (E)-Methyl 4-coumarate (HY-N2492). This product is intended for research and analytical applications. (E)-Methyl 4-coumarate (Methyl 4-hydroxycinnamate) is a phenolic compound and derivative of Cinnamic acid (HY-N0610A). (E)-Methyl 4-coumarate can be found in several plants, such as the leaves of Allium cepa and Morinda citrifolia L. (E)-Methyl 4-coumarate, when combined with Carnosic acid (HY-N0644), induces Apoptosis. (E)-Methyl 4-coumarate inhibits GSK3β activity and modulates inflammatory cytokine levels (increasing IL-10 and decreasing IL-4). (E)-Methyl 4-coumarate combined with Carnosic acid exhibits anticancer effects against acute myeloid leukemia. (E)-Methyl 4-coumarate ameliorates Plasmodium berghei NK65 infection.

Chitohexaose hexahydrochloride is a small molecular polysaccharide. Chitohexaose hexahydrochloride inhibits the binding of AgW to TLR4. Chitohexaose hexahydrochloride upregulates IL-10, inhibits LPS-induced upregulation of ROS, induces alternative activation of macrophages/monocytes, and suppresses LPS-induced production of TNF-α, IL-1β and IL-6. Chitohexaose hexahydrochloride reverses the mortality of mice challenged with APAP or LPS. Chitohexaose hexahydrochloride can be used in research related to Acetaminophen (HY-66005)-induced hepatotoxicity and endotoxemia.